lifestyle.ukuncut.org.uk

Author: Entrada Therapeutics, Inc.

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

May 6, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

February 17, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences

February 9, 2026